Clinical Trials Logo
  1. Home
  2. Genital Warts
  3. NCT02462187

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Genital Warts Clinical Trial

Official title:
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts

Clinical Trial Summary

A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts

Clinical Trial Description

This is a phase 2, multi-center, randomized, double-blind, vehicle-controlled, ascending dose study to assess safety, tolerability and efficacy of a topical nitric oxide releasing compound in subjects with external genital and perianal warts. Eligible subjects will be treated with a topical gel (active or vehicle) for up to 12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02462187
Study type Interventional
Source Novan, Inc.
Contact
Status Completed
Phase Phase 2
Start date June 12, 2015
Completion date October 17, 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Completed NCT03158220 - Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Phase 3
Completed NCT01651949 - Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Phase 3
Completed NCT00551187 - A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Phase 2
Completed NCT00520598 - Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Phase 2
Terminated NCT01468636 - A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Phase 4
Recruiting NCT03296397 - Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response Phase 3
Active, not recruiting NCT05314023 - Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) Phase 3
Completed NCT00674739 - Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Phase 3
Recruiting NCT03948321 - Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Small Genital Warts N/A
Completed NCT00862810 - Alternate Dosing Schedules Study for HPV Vaccine Phase 4
Completed NCT02280642 - Alternate Dosing Schedules Study for HPV Vaccine (ADS) Phase 4
Completed NCT00092482 - Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Phase 3
Completed NCT02188004 - The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
Completed NCT01553994 - Effectiveness Study of Gardasil on Condyloma N/A
Completed NCT00189293 - Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Phase 4
Active, not recruiting NCT00092534 - Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) Phase 3
Completed NCT00501137 - A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Phase 3
Active, not recruiting NCT02750202 - Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts Phase 3
Active, not recruiting NCT02653118 - Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)